SUBSTANCE FOR RESTORING NORMAL CO-EXPRESSION AND INTERACTION BETWEEN THE LOX AND NRAGE PROTEINS

The disclosed substance restores normal co-expression and interaction between the LOX and NRAGE proteins. Particularly, an effective amount of the substance that modulates the expression and/or activity of LOX of SEQ ID NO: 1 and/or that modulates the expression and/or activity of NRAGE of SEQ ID NO: 2, may be used for the manufacture of a composition for modulating the interaction between the LOX and NRAGE proteins to regulate the balance between the cellular phenomena of proliferation, differentiation and apoptosis, particularly in cases where the balance between these phenomena is disturbed, and especially in cases where the interaction between LOX and NRAGE is absent or altered. The invention makes it possible especially to treat and/or prevent skin ageing, lichen planus, graft-versus-host reaction (GVH), eczema, psoriasis and a cancer, particularly an epithelial cancer and more particularly a cutaneous epithelial cancer of basocellular or spinocellular type. 140-. (canceled)41Prunus spinosaArbutus unedoChimaphila umbellataCassia amaraTheobroma cacaoSmilax ornataFoeniculumRibes rubrumCitrus reticulataHumulus lupulusBrassica campestrisPekinensis. A method for stimulating expression or activity , or for stimulating both expression and activity , of a LOX having the amino acid sequence of SEQ ID NO: 1 comprising topically administering onto the skin an effective amount of at least one substance selected from the group consisting of a extract , an extract , a extract , a extract , a extract , a extract , a extract , a extract , a extract , a extract , and a var. extract , wherein the substance stimulates expression or activity , or both expression and activity , of the LOX.42. The method of claim 41 , wherein the substance further inhibits or stimulates expression of an NRAGE having the amino acid sequence of SEQ ID NO: 2.43. The method of claim 41 , wherein the substance stimulates the expression of the LOX.44. The method of claim 42 , wherein the substance ...

Stimulation of the synthesis of the activity of an isoform of lysyl oxidase-like loxl for stimulating the formation of elastic fibers

The invention relates to the stimulation of the synthesis and of the activity of an isoform of lysyl oxidase, and more particularly of the LOXL (lysyl oxidase-like) isoform. The invention relates notably to a method of identifying an active principle which stimulates the formation of elastic fibers. The aim of the invention is mainly to provide such a method of identification so as to provide compositions which enable stimulating the formation of elastic fibers.

SUBSTANCE FOR RESTORING NORMAL CO-EXPRESSION AND INTERACTION BETWEEN THE LOX AND NRAGE PROTEINS

The invention relates to the use of a substance for restoring normal co-expression and interaction between the LOX and NRAGE proteins. The invention relates in particular to the use of an effective amount of at least one substance that modulates the expression and/or activity of the LOX of SEQ ID NO: 1 and/or that modulates the expression and/or activity of the NRAGE of SEQ ID NO: 2 for modulating the interaction between the LOX and NRAGE proteins to regulate the balance between the cellular proliferation, differentiation and apoptosis, particularly in cases where the balance between these phenomena is disturbed, and especially in cases where the interaction between LOX and NRAGE is absent or altered. The invention makes it possible to treat skin ageing, lichen planus, graft-versus-host reaction (GVH), eczema, psoriasis and a cancer, particularly an epithelial cancer and more particularly a cutaneous epithelial cancer of basocellular or spinocellular type. 1. A method for regulating balance between cellular proliferation , differentiation and apoptosis in epithelial cells , comprising applying a pharmaceutical or cosmetic composition onto an epidermis in need thereof , wherein said composition comprises an effective amount of:i) at least one active ingredient that modulates expression of the lysyl oxidase (LOX) having the amino acid sequence of SEQ ID NO: 1;ii) at least one active ingredient that modulates expression of the NRAGE having the amino acid sequence of SEQ ID NO: 2; oriii) a combination of the active ingredient of i) and the active ingredient of ii).2. The method of claim 1 , wherein the epithelial cells are keratinocytes.3. The method of claim 2 , wherein the active ingredient of i) increases the expression of the lysyl oxidase by about 50% in the keratinocytes.4. The method of claim 2 , wherein the active ingredient of i) decreases the expression of the lysyl oxidase by about 50% in the keratinocytes.5. The method of claim 2 , wherein the active ...

COSMETIC USE OF HEPARAN SULPHATE

Affinity purification of fibroblast growth factor 2-binding heparan sulphate from porcine mucosa (HS8) is disclosed. Also disclosed is a process for the care of keratinous material(s), comprising the application or administration of HS8, or a composition comprising thereof, to keratinous material(s). The composition may be used to improve the condition of skin, such as smoothing the skin, restoring skin elasticity and firmness, or decreasing or preventing wrinkles, and may be formulated for topical or transdermal administration. 1. A process for the care of keratinous material(s) , the process comprising the application or administration of heparan sulphate HS8 , or a composition comprising HS8 , to keratinous material(s).2. The process of claim 1 , wherein the keratinous material(s) is selected from one or more of the human skin claim 1 , hair or nails claim 1 , preferably the skin.3. The process of or claim 1 , wherein heparan sulphate HS8 is used or is present in the composition in a content ranging from 0.0001% to 5% by weight claim 1 , preferably from 0.0001% to 2% by weight claim 1 , and still preferably from 0.001 to 2% by weight claim 1 , relative to the total weight of the composition.4. The process according to any one of to claim 1 , wherein said process is intended to decrease and/or prevent the signs of the ageing of the keratinous material(s).5. The process according to any one of to claim 1 , wherein said process is intended to maintain and/or stimulate moisturization and/or combat drying-out of the keratinous material(s).6. The process according to any one of to claim 1 , wherein said process is intended to:(i) decrease and/or prevent the characteristics of wrinkles, small wrinkles and/or fine lines of the skin;(ii) improve and/or decrease the microrelief of the skin;(iii) smooth the skin;(iv) improve the density of the skin;(v) maintain and/or restore skin elasticity;(vi) maintain and/or restore skin firmness;(vii) maintain and/or restore the ...

Cosmetic use of heparan sulphate

Affinity purification of fibroblast growth factor 2-binding heparan sulphate from porcine mucosa (HS8) is disclosed. Also disclosed is a process for the care of keratinous material(s), comprising the application or administration of HS8, or a composition comprising thereof, to keratinous material(s). The composition may be used to improve the condition of skin, such as smoothing the skin, restoring skin elasticity and firmness, or decreasing or preventing wrinkles, and may be formulated for topical or transdermal administration.

METHODS AND COMPOSITIONS FOR IMPROVING SKIN

PROCEDES ET COMPOSITIONS POUR L’AMELIORATION DE LA PEAU Procédé de gestion du teint de la peau comprenant la réduction de la synthèse de mélanine par l’application d’une composition de traitement de la peau sur la peau. La composition de traitement de la peau peut inclure environ 0,1 à environ 25 % en poids d’acétyl trifluorométhylphényl valylglycine ; environ 0,5 à environ 30 % en poids d’un polyol ; environ 0,1 à environ 30 % en poids d’un silicone, d’un composé gras, ou d’un mélange de ceux-ci, dans laquelle la composition de traitement de la peau est une émulsion, et tous les pourcentages en poids sont basés sur le poids total de la composition de traitement de la peau Figure pour l’abrégé : 1 METHODS AND COMPOSITIONS FOR SKIN IMPROVEMENT A method of managing skin tone comprising reducing melanin synthesis by applying a skin treatment composition to the skin. The skin treatment composition can include about 0.1 to about 25% by weight acetyl trifluoromethylphenyl valylglycine; about 0.5 to about 30% by weight of a polyol; about 0.1 to about 30% by weight of a silicone, fatty compound, or mixture thereof, wherein the skin treatment composition is an emulsion, and all weight percentages are based on the total weight of the skin treatment composition Figure for the abstract: 1

STIMULATION OF THE SYNTHESIS AND ACTIVITY OF A LYSYL OXIDASE-LIKE LOXL ISOFORM TO STIMULATE THE FORMATION OF ELASTIC FIBERS

The invention relates to the stimulation of the synthesis and of the activity of an isoform of lysyl oxidase, and more particularly of the LOXL (lysyl oxidase-like) isoform. The invention relates notably to a method of identifying an active principle which stimulates the formation of elastic fibers. The aim of the invention is mainly to provide such a method of identification so as to provide compositions which enable stimulating the formation of elastic fibers.

SUBSTANCE FOR RESTORING NORMAL CO-EXPRESSION AND INTERACTION BETWEEN LOX AND NRAGE PROTEINS

compositions comprising extracellular vesicles, secreted biomolecules and/or conditioned media, and methods for producing them

compositions comprenant des vésicules extracellulaires, des biomolécules sécrétées et/ou des milieux conditionnés, et procédés pour les produire La divulgation concerne de nouvelles compositions comprenant des 1) milieux conditionnés, 2) des combinaisons de biomolécules sécrétées/molécules organiques, et/ou 3) des vésicules extracellulaires sécrétées/exosomes prélevées à partir d'une culture de cellules épithéliales différenciées, tous uniques, ainsi que des procédés de fabrication et d'utilisation de telles compositions. Figure pour l'abrégé : 1 compositions comprising extracellular vesicles, secreted biomolecules and/or conditioned media, and methods for producing them Disclosed are novel compositions comprising 1) conditioned media, 2) combinations of secreted biomolecules/organic molecules, and/or 3) secreted extracellular vesicles/exosomes taken from a culture of differentiated epithelial cells, all of which are unique, as well as methods of making and using such compositions. Figure for abstract: 1

Methods and compositions for improving the skin

Procédés et compositions pour l’amélioration de la peau Procédé d’amélioration de la peau comprenant la réduction de la fonction de barrière de la peau, et l’application d’une composition de traitement de la peau sur la peau. La composition de traitement de la peau peut inclure environ 0,1 à environ 25 % en poids d’acétyl trifluorométhylphényl valylglycine ; environ 0,5 à environ 30 % en poids d’un polyol ; environ 0,1 à environ 30 % en poids d’un silicone, d’un composé gras, ou d’un mélange de ceux-ci, dans laquelle la composition de traitement de la peau est une émulsion, et tous les pourcentages en poids sont basés sur le poids total de la composition de traitement de la peau. Figure pour l’abrégé : Néant Methods and compositions for improving the skin A method of improving the skin comprising reducing the barrier function of the skin, and applying a skin treatment composition to the skin. The skin treatment composition can include about 0.1 to about 25% by weight acetyl trifluoromethylphenyl valylglycine; about 0.5 to about 30% by weight of a polyol; about 0.1 to about 30% by weight of a silicone, a fatty compound, or a mixture thereof, wherein the skin treatment composition is an emulsion, and all percentages by weight are based on the total weight of the skin treatment composition. Figure for abstract: None

Identifying substances that promote activity or production of the LOX isoform of lysyl oxidase, useful for correcting abnormal or pathological elastogenesis, e.g. in cases of fibrosis

Identifying a substance (X) that promotes activity and/or formation of the LOX isoform of lysyl oxidase, for regulating elastogenesis where this is abnormal or pathological, comprises contacting test compounds with cells, preferably living, that express LOX and analysis of LOX expression, particularly to identify stimulators of LOX expression. Independent claims are also included for the following: (1) locating expression of LOX, and optionally also of elastin, in tissues so as to track new formation of collagen and/or elastin, by immunodetection of LOX and optionally also elastin; (2) use of LOX comprising a fully defined 417 amino acid sequence, for regulating elastogenesis where this is abnormal or pathological; and (3) cosmetic, nutriceutical or pharmaceutical composition that contains (X) or LOX, optionally also an excipient. ACTIVITY : Cytostatic; Dermatological; Vulnerary. No details of tests for these activities are given. MECHANISM OF ACTION : (X) reduce or inhibit synthesis of elastin (or its precursor tropoelastin); LOX expression stimulator.

Stimulation of the activity of an isoform of lysyl oxidase for combating against some pathologies due to an incomplete, absent or disorganized elastogenesis

The invention relates to the stimulation of the activity of an isoform of lysyl oxidase, and more particularly of the LOX (lysyl oxidase) isoform. The invention relates notably to a screening method of an active principle which regulates elastogenesis in cases of pathological, disorganized and/or non-functional elastogenesis, as in cases of fibrosis, of solar elastosis, of stretch marks, and/or of dystrophic scars; and/or in cases of some eczematous pathologies. The aim of the invention is mainly to provide such a screening method so as to provide compositions enabling the elastogenesis in the cases cited to be regulated.

Cosmetic use by topical application of the lysyl oxidase-like (LOXL) enzyme to stimulate formation of skin elastic fibres

The invention relates to the stimulation of the synthesis and of the activity of an isoform of lysyl oxidase, and more particularly of the LOXL (lysyl oxidase-like) isoform. The invention relates notably to a method of identifying an active principle which stimulates the formation of elastic fibers. The aim of the invention is mainly to provide such a method of identification so as to provide compositions which enable stimulating the formation of elastic fibers.

Substance for restoring normal co-expression and interaction between lox and nrage proteins

The invention concerns a substance for restoring normal co-expression and interaction between LOX and NRAGE proteins. In particular, the invention concerns the use of an effective amount of at least one substance modulating the expression and/or the activity of LOX having the sequence ID N°1 and/or modulating the expression and/or the activity of NRAGE having the sequence ID N°2 for making a composition for modulating the interaction between the LOX and NRAGE proteins so as to regulate the balance between the phenomena of proliferating cells, of differentiation and apoptosis, in particular in cases where the interaction between LOX and NRAGE proteins is absent or altered. The invention enables in particular skin aging, lichen planus, a graft-versus-host reaction disease, an eczema, a psoriasis, and a cancer, in particular an epithelial cancer, particularly an epithelial skin cancer, of basocellular type, or of spinocellular type to prevented or treated.

STIMULATION OF THE SYNTHESIS AND ACTIVITY OF A LYSYL OXIDASE-LIKE LOXL ISOFORM TO STIMULATE THE FORMATION OF ELASTIC FIBERS

L'invention concerne la stimulation de la synthèse et de l'activité d'une isoforme de la lysyl oxydase, et plus particulièrement de l'isoforme LOXL (lysyl oxidase-like).L'invention concerne notamment une méthode d'identification d'un principe actif stimulant la formation de fibres élastiques.L'invention a principalement pour but de fournir une telle méthode d'identification afin de réaliser des compositions permettant de stimuler la formation de fibres élastiques. The invention relates to the stimulation of the synthesis and the activity of an isoform of lysyl oxidase, and more particularly of the LOXL isoform (lysyl oxidase-like). The invention relates in particular to a method for the identification of an active principle stimulating the formation of elastic fibers.The invention is mainly intended to provide such an identification method in order to produce compositions for stimulating the formation of elastic fibers.

Stimulation of the synthesis and of the activity of an isoform of lysyl oxidase-like loxl for stimulating the formation of elastic fibres

The invention relates to the stimulation of the synthesis and of the activity of an isoform of lysyl oxidase, and more particularly of the LOXL (lysyl oxidase-like) isoform. The invention relates notably to a method of identifying an active principle which stimulates the formation of elastic fibres. The aim of the invention is mainly to provide such a screening method so as to provide compositions which enable stimulating the formation of elastic fibres.

Methods and compositions for improving skin

A method for improving skin comprising reducing the barrier function of skin, and applying a skin treatment composition to the skin. The skin treatment composition may include about 0.1 to about 25 wt. % of acetyl trifluoromethylphenyl valylglycine; about 0.5 to about 30 wt. % of a polyol; about 0.1 to about 30 wt. % of a silicone, fatty compound, or a mixtures thereof, wherein the skin treatment composition is an emulsion, and all weight percentages are based on the total weight of the skin treatment composition.

Compositions and methods for skin

The disclosure relates to compositions and methods for preventing, reducing, and/or treating scars. The compositions comprise at least one C-glycoside or derivative thereof, and the methods comprise treating skin and/or scar tissue with at least one C-glycoside or derivative thereof and at least one skin modification stimulus.

compositions et procédés pour améliorer l’aspect de la peau

compositions et procédés pour améliorer l’aspect de la peau La divulgation concerne des compositions, des procédés et des nécessaires pour améliorer l’aspect de la peau en appliquant sur la peau de l’acétyl trifluorométhylphényl valylglycine, au moins un rétinoïde, et facultativement au moins un agent de gommage de la peau supplémentaire. Figure pour l’abrégé : figure 4

Modified peptides, composition, method for inhibiting contraction of muscle cells, method for improving the skin and use of a modified peptide

The invention relates to modified peptides comprising an amino acid sequence of SEQ ID NO: 1 to 80 and a N- and/or C- terminal modification, preferably with an acetyl and/or a carboxyl group modification. The present invention also relates to a composition comprising said modified peptides, to methods for inhibiting contraction of muscle cells and for improving the skin, and the use of said modified peptide.

Kit, method for screening an active compound in vitro and uses of a kit

The present invention relates to a kit comprising a co-culture microdevice containing peripheral sensory neurons (PSN) and human epidermal keratinocytes (HEK) in a cell culture adapted for both cell types. It is also described a method for screening an active compound using the kit according to the present invention, as well as the use thereof for in vitro dmg tests and for producing a cosmetic product for various dermatological applications, such as atopic dermatitis, sensitive skin, photoaging, wound healing and epidermal thickness in aged skin.

Compositions and methods for improving the appearance of skin

The disclosure relates to compositions, methods, and kits for improving the appearance of the skin by applying acetyl trifluoromethylphenyl valylglycine, at least one retinoid, and optionally at least one additional skin peeling agent to the skin.

Compositions and methods for preventing and/or treating scars

The disclosure relates to compositions and methods for preventing, reducing, and/or treating scars. The compositions comprise at least one C-glycoside or derivative thereof, and the methods comprise treating skin and/or scar tissue with at least one C-glycoside or derivative thereof and at least one skin modification stimulus.

Kit, method for screening an active compound in vitro and uses of a kit

The present invention relates to a kit comprising a co-culture microdevice containing peripheral sensory neurons (PSN) and human epidermal keratinocytes (HEK) in a cell culture adapted for both cell types. It is also described a method for screening an active compound using the kit according to the present invention, as well as the use thereof for in vitro drug tests and for producing a cosmetic product for various dermatological applications, such as atopic dermatitis, sensitive skin, photoaging, wound healing and epidermal thickness in aged skin.

Kit, method for screening an active compound in vitro and uses of a kit

The present invention relates to a kit comprising a co-culture microdevice containing peripheral sensory neurons (PSN) and human epidermal keratinocytes (HEK) in a cell culture adapted for both cell types. It is also described a method for screening an active compound using the kit according to the present invention, as well as the use thereof for in vitro drug tests and for producing a cosmetic product for various dermatological applications, such as atopic dermatitis, sensitive skin, photoaging, wound healing and epidermal thickness in aged skin.

Compositions comprising extracellular vesicles, secreted biomolecules, and/or conditioned media, and methods of producing and using the same

The disclosure relates to novel compositions comprising 1) conditioned media, 2) combinations of secreted biomolecules/organic molecules, and/or 3) secreted extracellular vesicles/exosomes collected from differentiated epithelial cell culture, as well as methods of making and using such compositions.

Methods and compositions for improving skin

A method for managing skin tone comprising reducing the synthesis of melanin by applying a skin treatment composition to skin. The skin treatment composition may include about 0.1 to about 25 wt. % of acetyl trifluoromethylphenyl valylglycine; about 0.5 to about 30 wt. % of a polyol; about 0.1 to about 30 wt. % of a silicone, fatty compound, or a mixtures thereof, wherein the skin treatment composition is an emulsion, and all weight percentages are based on the total weight of the skin treatment composition.

compositions comprenant des vésicules extracellulaires, des biomolécules sécrétées et/ou des milieux conditionnés, et procédés pour les produire

compositions comprenant des vésicules extracellulaires, des biomolécules sécrétées et/ou des milieux conditionnés, et procédés pour les produire La divulgation concerne de nouvelles compositions comprenant des 1) milieux conditionnés, 2) des combinaisons de biomolécules sécrétées/molécules organiques, et/ou 3) des vésicules extracellulaires sécrétées/exosomes prélevées à partir d'une culture de cellules épithéliales différenciées, tous uniques, ainsi que des procédés de fabrication et d'utilisation de telles compositions. Figure pour l'abrégé : 1

Compositions et procédés pour améliorer l’aspect de la peau

Compositions et procédés pour améliorer l’aspect de la peau La divulgation concerne des compositions, des procédés, des régimes et des nécessaires pour améliorer l'aspect de la peau par application d'acétyl trifluorométhylphényl valylglycine et d’au moins un agent de gommage sur la peau. Figure pour l’abrégé : Néant

Compositions et procédés de prévention et/ou de traitement des cicatrices

Compositions et Procédés de PRÉVENTION ET/OU DE TRAITEMENT des cicatrices La divulgation concerne des compositions et des procédés de prévention, de réduction et/ou de traitement des cicatrices. Les compositions comprennent au moins un C-glycoside ou dérivé de celui-ci, et les procédés comprennent le traitement de la peau et/ou de tissu cicatriciel avec au moins un C-glycoside ou dérivé de celui-ci et au moins un stimulus de modification de la peau. Figure pour l'abrégé : néant

Methods and compositions for improving skin

A method for improving skin comprising reducing the barrier function of skin, and applying a skin treatment composition to the skin. The skin treatment composition may include about 0.1 to about 25 wt. % of acetyl trifluoromethylphenyl valylglycine; about 0.5 to about 30 wt. % of a polyol; about 0.1 to about 30 wt. % of a silicone, fatty compound, or a mixtures thereof, wherein the skin treatment composition is an emulsion, and all weight percentages are based on the total weight of the skin treatment composition.